Equities Analysts Offer Predictions for Laboratory Corp. of America Holdings’ Q1 2019 Earnings (LH)
Laboratory Corp. of America Holdings (NYSE:LH) – Equities research analysts at KeyCorp issued their Q1 2019 earnings per share estimates for shares of Laboratory Corp. of America in a research report issued to clients and investors on Wednesday, October 24th. KeyCorp analyst D. Hooker forecasts that the medical research company will earn $2.69 per share for the quarter. KeyCorp also issued estimates for Laboratory Corp. of America’s Q2 2019 earnings at $2.91 EPS, Q3 2019 earnings at $2.89 EPS, Q4 2019 earnings at $3.03 EPS and FY2020 earnings at $12.26 EPS.
Laboratory Corp. of America (NYSE:LH) last issued its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.14). Laboratory Corp. of America had a net margin of 13.27% and a return on equity of 17.13%. The business had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.84 billion. During the same period last year, the business earned $2.46 earnings per share. The company’s revenue was up 8.0% on a year-over-year basis.
Shares of NYSE LH opened at $154.53 on Monday. Laboratory Corp. of America has a 1 year low of $147.70 and a 1 year high of $190.35. The stock has a market cap of $15.75 billion, a P/E ratio of 16.10, a price-to-earnings-growth ratio of 1.46 and a beta of 0.97. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.55 and a quick ratio of 1.32.
A number of large investors have recently added to or reduced their stakes in LH. Migdal Insurance & Financial Holdings Ltd. increased its stake in Laboratory Corp. of America by 7,033.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 642 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 633 shares in the last quarter. Fort L.P. bought a new stake in Laboratory Corp. of America during the 2nd quarter valued at about $118,000. Squar Milner Financial Services LLC bought a new stake in Laboratory Corp. of America during the 2nd quarter valued at about $150,000. NuWave Investment Management LLC increased its stake in Laboratory Corp. of America by 5,786.7% during the 3rd quarter. NuWave Investment Management LLC now owns 883 shares of the medical research company’s stock valued at $154,000 after purchasing an additional 868 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC bought a new stake in shares of Laboratory Corp. of America in the first quarter worth approximately $155,000. Institutional investors and hedge funds own 92.21% of the company’s stock.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates through two segments, LabCorp Diagnostics and Covance Drug Development. It offers a range of clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C, prostate-specific antigen, tests for sexually-transmitted diseases, hepatitis C tests, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests that are used by hospitals, physicians and other healthcare providers and commercial clients to assist in the diagnosis, monitoring and treatment of diseases and medical conditions through the examination of substances in blood, tissues, and other specimens.
Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.